
Oncology NEWS International
- Oncology NEWS International Vol 5 No 5
- Volume 5
- Issue 5
N E W P R O D U C T
PALO ALTO, Calif--ALZA Corporation and U.S. Bioscience, Inc. have announced the availability of Ethyol (amifostine), which was FDA approved in December, 1995.
PALO ALTO, Calif--ALZA Corporation and U.S. Bioscience, Inc. haveannounced the availability of Ethyol (amifostine), which was FDAapproved in December, 1995.
The agent is indicated to reduce the cumulative renal toxicityassociated with repeated administration of cisplatin (Platinol)in patients with advanced ovarian cancer or non-small-cell lungcancer. In these settings, the clinical data do not suggest thatthe effectiveness of cisplatin-based chemotherapy regimens isaltered by use of Ethyol.
There are at present only limited data on the influence of Ethyolon the efficacy of chemotherapy in other settings; therefore,Ethyol should not be given to patients in other settings wherechemotherapy can produce a significant survival benefit or cure(eg, certain malignancies of germ cell origin), except in thecontext of a clinical study.
ALZA will be responsible for US sales and marketing of Ethyol.
Articles in this issue
almost 30 years ago
No Need to Delay Mammography After FNA, Study Showsalmost 30 years ago
Pediatric Cancer Guidelines Are a National Effortalmost 30 years ago
EPA Proposes Changes in Determining Cancer Risk of Chemicals, Pollutantsalmost 30 years ago
ATL's HDI Digital Ultrasound Is Approved for Breast Indicationalmost 30 years ago
NIH Study Suggests That 200 mg Is The Optimal Daily Dose of Vitamin Calmost 30 years ago
Natural History of HIV Supports the Use Of Early Interventionsalmost 30 years ago
Aids Vaccine Trial Fails to Show Clinical Benefitalmost 30 years ago
Rep. Porter Honored For Work on BudgetNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



















